Out of the shadows: CXC chemokines in promoting aberrant lung cancer angiogenesis

Cancer Prevention Research

Volumn 1, Issue 5, 2008, Pages 305-307

  Strieter, Robert M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE;

BIOLOGICAL MODEL; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; NEOVASCULARIZATION (PATHOLOGY); NOTE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULARIZATION;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOKINES, CXC; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 52649106572     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0168     Document Type: Review

References (18)

1. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002;64:993-8.
2. Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001;7:345-50.
3. Minet E, Michel G, Mottet D, Raes M, Michiels C. Transduction pathways involved in hypoxia-inducible factor-1 phosphorylation and activation. Free Radic Biol Med 2001;31:847-55.
4. Phillips RJ, Mestas J, Gharaee-Kermani M, et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on nonsmall cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/ mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1α. J Biol Chem 2005;280:22473-81.
5. Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 2003;112:645-57.
6. Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-8.
7. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309.
8. Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis. J Leukoc Biol 2000; 68:1-8.
9. Mizukami Y, Jo WS, Duerr EM, et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1α-deficient colon cancer cells. Nat Med 2005; 11:992-7.
10. Sun H, Chung W-C, Ryu S-H, et al. Cyclic AMP-Responsive element binding protein- and nuclear factor-κB-regulated CXC chemokine gene expression in lung carcinogenesis. Cancer Prev Res 2008;1:316-28.
11. Addison CL, Daniel TO, Burdick MD, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 2000;165:5269-77.
12. Best JL, Amezcua CA, Mayr B, et al. Identification of small-molecule antagonists that inhibit an activator: coactivator interaction. Proc Natl Acad Sci U S A 2004;101:17622-7.
13. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci U S A 1997;94:2927-32.
14. Hurst SD, Muchamuel T, Gorman DM, et al. New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J Immunol 2002;169:443-53.
15. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
16. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007;12:713-8.
17. Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM. Depletion of CXCR2inhi bits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 2004;172:2853-60.
18. Wislez M, Fujimoto N, Izzo JG, et al. High expression of ligands for chemokine receptor CXCR2in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res 2006;66:4198-207.